130 related articles for article (PubMed ID: 29733074)
1. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SJ; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Jan; 9(1):924-936. PubMed ID: 29416667
[TBL] [Abstract][Full Text] [Related]
3. Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
Li X; Yin X; Wang H; Huang J; Yu M; Ma Z; Li C; Zhou Y; Yan X; Huang S; Jin J
Oncotarget; 2019 Nov; 10(61):6641-6642. PubMed ID: 31762943
[TBL] [Abstract][Full Text] [Related]
4. Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():21. PubMed ID: 31636908
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.
Latuske EM; Stamm H; Klokow M; Vohwinkel G; Muschhammer J; Bokemeyer C; Jücker M; Kebenko M; Fiedler W; Wellbrock J
Oncotarget; 2017 Apr; 8(17):29187-29201. PubMed ID: 28418873
[TBL] [Abstract][Full Text] [Related]
6. Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.
Li J; Xu J; Abruzzo LV; Tang G; Li S; You MJ; Lu G; Jabbour EJ; Deng Q; Bueso-Ramos CE; Medeiros LJ; Yin CC
Oncotarget; 2018 Sep; 9(76):34449. PubMed ID: 30344953
[TBL] [Abstract][Full Text] [Related]
7. Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
Sun H; Lin DC; Guo X; Masouleh BK; Gery S; Cao Q; Alkan S; Ikezoe T; Akiba C; Paquette R; Chien W; Müller-Tidow C; Jing Y; Agelopoulos K; Müschen M; Koeffler HP
Oncotarget; 2017 Sep; 8(38):64651. PubMed ID: 28969101
[TBL] [Abstract][Full Text] [Related]
8. Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Mosquera Orgueira A; Peleteiro Raíndo A; Cid López M; Antelo Rodríguez B; Díaz Arias JÁ; Ferreiro Ferro R; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; Melero Valentín P; Sonia González Pérez M; Cerchione C; Martinelli G; Montesinos Fernández P; Mateo Pérez Encinas M; Luis Bello López J
PLoS One; 2022; 17(9):e0274984. PubMed ID: 36107965
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
10. Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2019 Sep; 10(52):5493. PubMed ID: 31534634
[TBL] [Abstract][Full Text] [Related]
11. Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
Patkar N; Kodgule R; Kakirde C; Raval G; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Kadechkar S; Khizer SH; Kannan S; Shetty D; Gokarn A; Punatkar S; Jain H; Bagal B; Menon H; Sengar M; Khattry N; Tembhare P; Subramanian P; Gujral S
Oncotarget; 2019 Jan; 10(5):617. PubMed ID: 30728913
[TBL] [Abstract][Full Text] [Related]
12. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.
Dehmel U; Zaborski M; Meierhoff G; Rosnet O; Birnbaum D; Ludwig WD; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):261-70. PubMed ID: 8637235
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
[TBL] [Abstract][Full Text] [Related]
14. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
15. Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; García Garay MC; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2018 Aug; 9(67):32881. PubMed ID: 30214691
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
17. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
[TBL] [Abstract][Full Text] [Related]
18. Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.
Lamba JK; Cao X; Raimondi SC; Rafiee R; Downing JR; Shi L; Gruber T; Ribeiro RC; Rubnitz JE; Pounds SB
Oncotarget; 2018 Jul; 9(54):30473. PubMed ID: 30101002
[TBL] [Abstract][Full Text] [Related]
19. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
[TBL] [Abstract][Full Text] [Related]
20. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells.
Drexler HG; Meyer C; Quentmeier H
Leuk Lymphoma; 1999 Mar; 33(1-2):83-91. PubMed ID: 10194124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
